217 related articles for article (PubMed ID: 12823591)
1. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.
Bozdayi AM; Uzunalimoğlu O; Türkyilmaz AR; Aslan N; Sezgin O; Sahin T; Bozdayi G; Cinar K; Pai SB; Pai R; Bozkaya H; Karayalçin S; Yurdaydin C; Schinazi RF
J Viral Hepat; 2003 Jul; 10(4):256-65. PubMed ID: 12823591
[TBL] [Abstract][Full Text] [Related]
2. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
3. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
[TBL] [Abstract][Full Text] [Related]
4. Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population.
Alagozlu H; Ozdemir O; Koksal B; Yilmaz A; Coskun M
Asian Pac J Cancer Prev; 2013; 14(9):5489-94. PubMed ID: 24175847
[TBL] [Abstract][Full Text] [Related]
5. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
Wu F; Wu MJ; Zhuge XL; Zhu SM; Zhu B
Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):172-6. PubMed ID: 22484586
[TBL] [Abstract][Full Text] [Related]
7. [HBV gene variants and polymerse gene mutations in children with chronic hepatitis B in the course of the antiviral therapy].
Góra-Gebka M; Liberek A; Charmuszko U; Sikorska-Wiśniewska G; Szlagatys-Sidorkiewicz A; Korzon M; Bielawski K
Med Wieku Rozwoj; 2007; 11(4):367-71. PubMed ID: 18605187
[TBL] [Abstract][Full Text] [Related]
8. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.
Lee YS; Chung YH; Kim JA; Kim SE; Shin JW; Kim KM; Lim YS; Park NH; Lee HC; Lee YS; Suh DJ
Liver Int; 2009 Apr; 29(4):552-6. PubMed ID: 19323782
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
12. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
[TBL] [Abstract][Full Text] [Related]
13. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
14. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J
J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
[TBL] [Abstract][Full Text] [Related]
17. HBV mutations associated with lamivudine therapy.
Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
[TBL] [Abstract][Full Text] [Related]
18. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y
J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
Deng H; Lv Y; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.
Liu KZ; Hou W; Zumbika E; Ni Q
J Zhejiang Univ Sci B; 2005 Dec; 6(12):1182-7. PubMed ID: 16358376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
